Cerus Corporation (CERS): Price and Financial Metrics


Cerus Corporation (CERS)

Today's Latest Price: $6.58 USD

0.56 (9.30%)

Updated Nov 27 1:00pm

Add CERS to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 389 in Biotech

See all "A" rated Strong Buy stocks

CERS Stock Summary

  • CERS's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 197.27 -- higher than 84.67% of US-listed equities with positive expected earnings growth.
  • CERS's price/sales ratio is 10.26; that's higher than the P/S ratio of 85.51% of US stocks.
  • As for revenue growth, note that CERS's revenue has grown 22.42% over the past 12 months; that beats the revenue growth of 80.81% of US companies in our set.
  • Stocks that are quantitatively similar to CERS, based on their financial statements, market capitalization, and price volatility, are EPZM, MRAM, JG, PSNL, and KIN.
  • Visit CERS's SEC page to see the company's official filings. To visit the company's web site, go to www.cerus.com.

CERS Stock Price Chart Interactive Chart >

Price chart for CERS

CERS Price/Volume Stats

Current price $6.58 52-week high $7.94
Prev. close $6.02 52-week low $2.71
Day low $6.12 Volume 1,302,900
Day high $6.58 Avg. volume 1,777,946
50-day MA $6.13 Dividend yield N/A
200-day MA $5.91 Market Cap 1.10B

Cerus Corporation (CERS) Company Bio


Cerus Corporation operates as a biomedical products company which focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company was founded in 1991 and is based in Concord, California.


CERS Latest News Stream


Event/Time News Detail
Loading, please wait...

CERS Latest Social Stream


Loading social stream, please wait...

View Full CERS Social Stream

Latest CERS News From Around the Web

Below are the latest news stories about Cerus Corp that investors may wish to consider to help them evaluate CERS as an investment opportunity.

Cerus Corporation Announces Schedule of Presentations at the AABB 2020 Virtual Annual Meeting

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) announced today its lineup of abstract presentations at the AABB 2020 Virtual Annual Meeting, which will take place on October 3rd through October 5th. This year’s Virtual Annual Meeting remains one of the largest scientific symposiums focused on the field of transfusion medicine. Scientists and clinicians from around the globe will share the latest research and practice-changing resources in the fields of blood and biotherapies.

Business Wire | September 28, 2020

Cerus Corporation to Participate in Upcoming Virtual Investor Conferences

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) announced today that William ‘Obi’ Greenman, Cerus’ president and chief executive officer, and Kevin D. Green, Cerus’ chief financial officer, are scheduled to participate in the following two conferences: The Cantor Fitzgerald Virtual Global Healthcare Conference on Tuesday, September 15th at 2:00 P.M. ET. The H.C. Wainwright 22nd Annual Global Investment Conference on Wednesday, September 16th at 12:00 P.M. ET. A live webcast o

Business Wire | September 9, 2020

The Daily Biotech Pulse: Altimmune Reports Positive Preclinical Data For Intranasal COVID-19 Vaccine, AbbVie Licenses Morphic's Drug, Viveve Clinical Readout

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 24) Abbott Laboratories (NYSE: ABT ) Cancer Genetics Inc (NASDAQ: CGIX ) (announced a deal to buy organoid start up company StemoniX) Cardiff Oncology Inc (NASDAQ: CRDF ) Catabasis Pharmaceuticals Inc (NASDAQ: CATB ) Cerus Corporation (NASDAQ: CERS ) (moved on FDA's emergency use authorization for plasma therapy as a potential COVID-19 treatment) ESSA Pharma Inc (NASDAQ: EPIX ) Fortress Biotech (NASDAQ: FBIO ) Inozyme Pharma Inc (NASDAQ: INZY ) Kamada Ltd. (NASDAQ: KMD) (reacted to the news of EUA for plasma anti-COVID-19 therapy) Keros Therapeutics Inc (NASDAQ: KROS ) Lantern Pharma Inc. (NASDAQ: LTRN ) Mirati Therapeutics Inc (NASDAQ: MRTX ) Pacific Biosciences of California Inc (NASDAQ: PACB ) Principia Biopharma Inc (NASDA...

Benzinga | August 25, 2020

Cerus INTERCEPT Blood System Kit Shipments Surpass 7.5 Million Treatable Platelet and Plasma Doses Since Launch

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) announced today that INTERCEPT Blood Systems disposable kit shipments have surpassed 7.5 million treatable platelet and plasma doses globally since commercial launch. “This is a significant milestone for Cerus and highlights the scope our technology has had within the transfusion industry and on the millions of patients worldwide transfused with INTERCEPT treated platelet and plasma components,” said William ‘Obi’ Greenman, Cerus

Business Wire | August 7, 2020

Cerus Corporation Announces Record Second Quarter 2020 Results

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced financial results for the second quarter ended June 30, 2020. Recent developments and highlights include: Q2 2020 Total Revenue of $26.8 million - driven by robust year-over-year platelet kit sales growth in the U.S. and strong plasma and illuminator sales in our EMEA region. Total revenue comprised of (in millions, except %): Q2 2020 Q2 2019 Change $ Change% Product Revenue $ 21.5 $ 18.2 $ 3.3 18.1% Government

Business Wire | August 4, 2020

Read More 'CERS' Stories Here

CERS Price Returns

1-mo 18.45%
3-mo 5.11%
6-mo 1.39%
1-year 51.61%
3-year 68.29%
5-year 16.05%
YTD 55.92%
2019 -16.77%
2018 50.00%
2017 -22.30%
2016 -31.17%
2015 1.28%

Continue Researching CERS

Want to see what other sources are saying about Cerus Corp's financials and stock price? Try the links below:

Cerus Corp (CERS) Stock Price | Nasdaq
Cerus Corp (CERS) Stock Quote, History and News - Yahoo Finance
Cerus Corp (CERS) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8308 seconds.